Clinical trials: in Finland
Hidradenitis Suppurativa
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
Hidradenitis suppurativa (HS) is an inflammatory skin disease that causes painful lesions in the axilla (underarm), inguinal (groin) and anogenital (anal/genital) regions.
- Trial name
- Step-Up HS (NCT05889182)
- Testing
- Upadacitinib
- Where
- 285 sites in United States, Argentina and 35 more
- Volunteers
- 1,328 people
- Sponsor
- AbbVie
Atrial Fibrillation
Real World Data Collection in Subjects Treated With the FARAPULSE Pulsed Field Ablation System
The goal of any novel design or therapeutic strategy to treat atrial fibrillation is to restore normal sinus rhythm and to reduce or eliminate the symptoms due to rapid atrial response.
- Trial name
- FARADISE (NCT05501873)
- Testing
- FARAPULSE Pulsed Field Ablation system
- Where
- 48 sites in Australia, Austria and 19 more
- Volunteers
- 1,173 people
- Sponsor
- Boston Scientific Corporation
Financial Difficulties
A Financial Social Work Intervention for Families With Complex Financial Difficulties (FinSoc)
As of 2022, about 12% of children in Finland lived in poverty. Many of these families face not only a lack of money but also stress, low confidence in managing finances, and limited access to financial guidance.
- Trial name
- FinSoc (NCT07084389)
- Testing
- FinSoc
- Where
- Finland
- Volunteers
- 136 people
- Sponsor
- University of Turku
Kidney Transplantation in Highly Sensitized Patients
Imlifidase Prior to Kidney Transplant in Highly Sensitised Children
The goal of this clinical trial is to learn about the efficacy and safety of imlifidase in highly sensitized paediatric patients, 1-17 years old, with end stage renal disease (ESRD).
- Trial name
- DINKY (NCT05753930)
- Testing
- Imlifidase
- Where
- 6 sites in Finland, France and 3 more
- Volunteers
- 10 people
- Sponsor
- Hansa Biopharma AB
Breast Carcinoma, Breast Cancer
Omission of Axillary Lymph Node Dissection in Case of Tumor Spread to Lymph Nodes in the Armpit in Breast Cancer
SENOMAC-ULTRA enrols patients who are planned for upfront surgery for a breast cancer that has spread to lymph nodes in the armpit, and that have been detected already prior to surgery by imaging, e.g. ultrasonography.
- Conditions
- Breast Carcinoma, Breast Cancer, Breast Surgery
- Trial name
- SENOMAC-ULTRA (NCT06869629)
- Testing
- Targeted axillary dissection, Axillary lymph node dissection
- Where
- 4 sites in Finland, South Korea and 1 more
- Volunteers
- 1,380 people
- Sponsor
- Karolinska Institutet
Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
This is a Phase 3 extension, global, multicenter study to assess the long-term safety and tolerability of tolebrutinib in adult participants (aged ≥18 years) with RMS, PPMS, or NRSPMS who were previously enrolled in the Phase 2b…
- Conditions
- Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
- Trial name
- NCT06372145
- Testing
- Tolebrutinib, Teriflunomide
- Where
- 352 sites in United States, Argentina and 45 more
- Volunteers
- 2,500 people
- Sponsor
- Sanofi
HCM - Hypertrophic Cardiomyopathy
Stratification, Management, and Guidance of Hypertrophic Cardiomyopathy Patients Using Hybrid Digital Twin Solutions
The goal of SMASH-HCM is to develop a digital twin or virtual model of the heart and vascular system with sympathetic nerve control that integrates multi-scale and multi-organ spatiotemporal biophysical data from a multitude of…
- Trial name
- SMASH-HCM (NCT07131371)
- Where
- Finland
- Volunteers
- 2,500 people
- Sponsor
- Tampere University
Prostate Cancer Metastatic
Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer
The purpose of this first-in-man study is to evaluate safety and tolerability of ODM-208 in patients with metastatic castration-resistant prostate cancer.
- Trial name
- CYPIDES (NCT03436485)
- Testing
- ODM-208, Midazolam
- Where
- 20 sites in United States, Finland and 2 more
- Volunteers
- 204 people
- Sponsor
- Orion Corporation, Orion Pharma
Surgical Complication
The Effect of Local Application of Tranexamic Acid Versus Placebo on Postoperative Complications in Plastic Surgery
Study objective: This is a study to investigate whether applying the drug tranexamic acid (TXA) onto a surgical wound surface may affect the incidence of surgical complications such as re-bleeding needing intervention, wound…
- Trial name
- TRANOP (NCT06270407)
- Testing
- Tranexamic Acid 100 MG/ML, 0.9%sodium chloride
- Where
- 11 sites in Denmark, Finland and 1 more
- Volunteers
- 3,000 people
- Sponsor
- St. Olavs Hospital
Paresis, Lumbar Disc Herniation
Validation of a Methodology Using Isometric Dynamometer for Ankle STrength Assessment to Quantify LDH-induced Paresis
Lumbar disc herniation (LDH) is a common condition that may cause lower limb motor weakness (paresis), particularly affecting ankle dorsiflexion and plantarflexion.
- Trial name
- VAST-LDH (NCT07763522)
- Testing
- Strength test validity and reliability
- Where
- Finland
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Helsinki University Central Hospital
Leukemia, Acute Lymphoblastic
A Treatment Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia
The pilot study collects the experience of previously successful treatment of infants, children and young adults, with ALL from a number of well-renowned study groups into a new platform protocol, which is both a comprehensive…
- Trial name
- NCT03911128
- Testing
- Observational
- Where
- 57 sites in Denmark, Estonia and 6 more
- Volunteers
- 500 people
- Sponsor
- Mats Heyman
Focal Epilepsy
Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
The purpose of this study is to determine whether BHV-7000 is effective in the treatment of refractory focal epilepsy.
- Trial name
- RISE 3 (NCT06309966)
- Testing
- BHV-7000
- Where
- 150 sites in United States, Australia and 14 more
- Volunteers
- 390 people
- Sponsor
- Biohaven Therapeutics Ltd.
Narcolepsy
A Trial to Test the Safety and Tolerability of Lu AH69593 in Adults That Are Healthy or Have Narcolepsy
The purpose of the trial is to determine if Lu AH69593 is safe and well tolerated. The trial will also look at how the body processes Lu AH69593 with and without food.
- Trial name
- NCT07613710
- Testing
- Lu AH69593
- Where
- 2 sites in Finland
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- H. Lundbeck A/S
Alpha 1-Antitrypsin Deficiency
Phase III, Efficacy and Safety of "Kamada-AAT for Inhalation"
The goal of this clinical trial is to learn if AAT for inhalation, at a dose of 80 mg/day can slow the progression of lung disease in people who have lung disease caused by severe genetic deficiency in Alpha 1 Antitrypsin (AATD).
- Trial name
- InnovAATe (NCT04204252)
- Testing
- Alpha 1-Antitrypsin
- Where
- 9 sites in Belgium, Finland and 4 more
- Volunteers
- 98 people
- Sponsor
- Kamada, Ltd.
Leukemia, Acute Lymphoblastic
A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia
ALLTogether collects the experience of previously successful treatment of infants, children and young adults, with ALL from a number of well-renowned study groups into a new master protocol, which is both a comprehensive system…
- Trial name
- NCT04307576
- Testing
- Omitted Doxorubicin, Omitted Vincristine+Dexamethasone pulses, Inotuzumab Ozogamicin+Standard Maintenance Therapy
- Where
- 137 sites in Belgium, Denmark and 13 more
- Volunteers
- 6,430 people
- Sponsor
- Mats Heyman
Infratentorial Neoplasms, Mutism
Cerebellar Mutism Syndrome Study
The purpose of this study is to determine why up to 25% of the pediatric patients who have surgery for a tumor in the posterior fossa develops the Cerebellar Mutism Syndrome (CMS).
- Trial name
- NCT02300766
- Where
- 32 sites in Austria, Belgium and 12 more
- Volunteers
- 2,000 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Hematological Malignancies
Dose-range Finding Treosulfan-based Conditioning
Evaluation of the safety and efficacy of 3 x 10, 3 x 12 or 3 x 14 g/m² Treosulfan resp., combined with 5 x 30 mg/m² fludarabine prior to allogeneic, hematopoietic stem cell transplantation of patients with hematological…
- Trial name
- NCT01063647
- Testing
- Treosulfan
- Where
- 7 sites in Finland, Germany and 2 more
- Volunteers
- 56 people
- Sponsor
- medac GmbH
Chronic Inflammatory Demyelinating Polyneuropathy
To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP
This is a multi-center, randomized, quadruple-blind, placebo-controlled study to evaluate the efficacy and safety of batoclimab in adult participants with active CIDP.
- Trial name
- NCT05581199
- Testing
- Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly, Batoclimab 340 mg SC weekly
- Where
- 98 sites in United States, Argentina and 19 more
- Volunteers
- 94 people
- Sponsor
- Immunovant Sciences GmbH
Ventilation Therapy, ALS
Initiation of Noninvasive Ventilation in ALS Patients With Chronic Respiratory Insufficiency
This research will study whether noninvasive ventilation (NIV) used to treat chronic respiratory insufficiency in patients with amyotrophic lateral sclerosis (ALS) can be initiated as successfully in the outpatient setting as in…
- Conditions
- Ventilation Therapy, ALS, Chronic Respiratory Failure
- Trial name
- InNIVALS (NCT06286917)
- Testing
- NIV initiation in patients with ALS
- Where
- Finland
- Volunteers
- 120 people
- Sponsor
- Tampere University
Breast Cancer
A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer
This is open-label, multicenter, international study, assessing the efficacy and safety of Trastuzumab deruxtecan (T-DXd) in participants with or without brain metastasis (BMs), with previously-treated advanced/metastatic…
- Trial name
- DESTINY-B12 (NCT04739761)
- Testing
- Trastuzumab Deruxtecan
- Where
- 81 sites in United States, Australia and 16 more
- Volunteers
- 506 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.